ABSTRACT

Objective: To monitor the systemic immune responses of patients with multiple sclerosis (MS) under treatment with GNbAC1, a monoclonal antibody against the envelope protein of the MS-associated retrovirus, during a phase 2a trial.

Methods: We analyzed the composition of immune cell subsets and the activation level of monocytes by flow cytometry and the response against viral and vaccine antigens by ELISpot.

Results: None of the endpoints measured revealed any immunosuppressive effect of the therapeutic antibody. Activation of monocytes slightly decreased during treatment as predicted by the hypothesized mechanism of action of GNbAC1.

Conclusion: These results support the conclusion that the antibody is safe for use in patients with MS.

Classification of evidence: This study provides Class III evidence that in patients with MS GNbAC1 does not significantly affect several biomarkers of systemic immune response. Neurology Neuroimmunol Neuroinflamm 2015;2:e144; doi: 10.1212/NXI.0000000000000144

GLOSSARY

CPT = cell preparation tube; env = envelope protein of MSRV; IFN = interferon; LPS = lipopolysaccharide; MAPK = mitogen-activated protein kinase; MBP = myelin basic protein; MS = multiple sclerosis; MSRV = MS-associated retrovirus; TLR4 = toll-like receptor 4.

Both genetic and environmental factors have been discussed in the pathogenesis of multiple sclerosis (MS). Endogenous retroviruses fall between genetics and environment, having been integrated into the human genome long ago and now being inherited like other genes. Several studies indicate that an endogenous retrovirus, the MS-associated retrovirus (MSRV), might be connected to MS pathogenesis. MSRV has been isolated from brain tissue of patients with MS.1 Subsequently, different studies found increased viral copy numbers and/or transcripts in blood, CSF, or brains of patients with MS compared with controls.2-4 Detection of MSRV was also correlated with disease severity and disability progression.5,6 MSRV might influence the pathogenesis of MS in 2 different ways: by targeting immune cells and by interacting with oligodendrocytes. It has been shown that the envelope protein of MSRV (env) can act as a ligand of toll-like receptor 4 (TLR4) and can activate cells expressing this receptor, such as monocytes, leading to an aberrant upregulation of immune reactivity, thus contributing to autoimmune pathology.7 It has also been suggested that env might directly compromise oligodendrocytes, possibly also via interaction with TLR4.8,9 It was therefore speculated that blocking the interaction between env and immune cells and/or oligodendrocytes might be a novel therapeutic option in MS. Recently, results were reported from a phase 2a trial of GNbAC1, a humanized monoclonal IgG4/k antibody against the
extracellular domain of env.\textsuperscript{10} This trial showed a favorable safety and pharmacokinetic profile of the therapeutic antibody and showed that MSRV transcripts declined during GNbAC1 treatment, indicating a pharmacodynamic effect. The immunologic substudy reported here examined blood samples from patients enrolled in the previously published phase 2a trial to assess the impact of the therapeutic antibody on the immune system. Additional healthy volunteers were recruited for comparison.

**METHODS Participants and design.** Blood samples were taken from the 10 patients involved in the phase 2a trial (5 from Basel, 5 from Geneva) and from 5 healthy volunteers recruited additionally for this immunologic substudy. Demographic details are provided in the table. Patients received monthly infusions of 2 or 6 mg/kg body weight over a period of 6 months. Blood was drawn on the day before the first administration of GNbAC1, on the first day after administration, 2 weeks after administration, and at the end of the 6-month treatment period. Two patients received placebo for the first time point. Blood from healthy controls was drawn at each time point on the same day as the patients and processed in parallel. A schematic of the study design is shown in figure e-1 at Neurology.org/nn.

**Standard protocol approvals, registrations, and patient consents.** The study protocol was approved by the ethics committees of both centers and the Swiss Medicine Agency, Swissmedic. All patients enrolled in this study gave written informed consent.

**Assays.** Blood taken from participants in Basel was processed immediately. In Geneva, blood was drawn into cell preparation tubes (CPT\textregistered{}s), transported to Basel by courier, and processed the same day. The primary research question was: How does the state of the immune system change following treatment with GNbAC1? This was addressed in 3 assays (Class III level evidence): (1) proportions of various immune cell populations by flow cytometry to monitor the general state of the immune system; (2) interferon (IFN)-\(\gamma\) production in response to various antigens, using the Ready-SET-go human IFN-\(\gamma\) ELISpot kit (eBioscience, San Diego, CA) to measure physiologic immune reactivity; and (3) p38 mitogen-activated protein kinase (MAPK) phosphorylation by phospho-specific flow cytometry (clone 36/p38, BD Biosciences, San Jose, CA) as a measure of TLR4 stimulation in monocytes. Immune cell subpopulations and ELISpot results are not reported from the Geneva patients, whose peripheral blood mononuclear cells after retrieval from CPT\textregistered{}s contained variable levels of erythrocytes, granulocytes, and other cell types, making comparisons unreliable. For the p38 MAPK phosphorylation, this problem was obviated by restricting flow cytometry to CD33-positive monocytes, and results are reported for all 10 patients and 4 controls.

**RESULTS** Using flow cytometry, we determined the frequencies of the main subfractions of lymphocytes during the trial. We could not detect a difference in the proportions of CD4\(^{+}\) and CD8\(^{+}\) T cells, B cells, and monocytes between patients and controls. There was also no change in the composition of lymphocytes during 6 months of treatment with GNbAC1 (figure 1A).

We monitored antigen-specific responses by IFN-\(\gamma\) ELISpot. We detected robust immune responses against varicella-zoster virus and tetanus vaccine (Tetanol) throughout the study. The responses were highly variable between individuals and across time but not obviously different between patients and controls (figure 1B). The presence of robust antivaccine and antiviral responses and the absence of antigen-independent IFN-\(\gamma\) production at similar levels before and after treatment suggest that there was no adverse activation or suppression of the protective immune response. We also tested the T cell response against an established autoantigen in MS, myelin basic protein (MBP). The response against MBP was low in patients and healthy controls and did not significantly change over time (data not shown).

To monitor TLR4 activation in monocytes, we determined the phosphorylation of p38, a key component of the signaling pathway downstream of TLR4, using a phospho-specific anti–p38 MAPK antibody in flow cytometry. We were able to detect the effect of lipopolysaccharide (LPS) down to 100 pg/mL (figure 1D), a level of sensitivity comparable to the gold standard Limulus amebocyte lysate endotoxin test. Primarily, we examined phosphorylation of p38 in naive monocytes (without exogenous LPS) before and during treatment. The pattern we observed was consistent with the hypothesis underlying the proposed mechanism of action of GNbAC1, i.e., before the trial, p38 phosphorylation was higher in patients with MS than in healthy controls, and treatment reduced the p38 phosphorylation in patients (figure 1C). However, this did not reach statistical significance.

<table>
<thead>
<tr>
<th>Table</th>
<th>Patient and control demographic characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristic</td>
<td>Patients (N = 10)</td>
</tr>
<tr>
<td>Age, y, mean ± SD</td>
<td>53.4 ± 6.6</td>
</tr>
<tr>
<td>Female/male</td>
<td>3/7</td>
</tr>
<tr>
<td>Diagnosis, n (%)</td>
<td></td>
</tr>
<tr>
<td>RRMS</td>
<td>1 (10.0)</td>
</tr>
<tr>
<td>PPMS</td>
<td>3 (30.0)</td>
</tr>
<tr>
<td>SPMS</td>
<td>6 (60.0)</td>
</tr>
<tr>
<td>EDSS, mean ± SD</td>
<td>4.8 ± 1.5</td>
</tr>
</tbody>
</table>

Abbreviations: EDSS = Expanded Disability Status Scale; NA = not applicable; PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis.
We also tracked p38 phosphorylation across the trial in naive monocytes and in response to various doses of LPS and observed that the response to this exogenous TLR4 ligand was similar between patients and controls and stable across the trial (figure 1D).
DISCUSSION These results are consistent with the previously published report of the phase 2a trial in that no evidence was obtained that GNbAC1 administration interferes with the normal functioning of the immune system. This apparent evidence of safety should be interpreted in light of the small size and limited duration of the trial. Flow cytometry of phospho-p38 in monocytes has potential as a biomarker for monitoring response to treatment with this antibody or any other agent targeting the TLR signaling system. Larger studies will be required to corroborate these findings and elucidate the relationship between monocyte activation and clinical response.

AUTHOR CONTRIBUTIONS


STUDY FUNDING

This work was supported by GeNeuro, SA, Plan-les-Ouates/Geneva, Switzerland.

DISCLOSURE

M. Zimmerman reports no disclosures. N.S.R. Sanderson received research support from Swiss National Science Foundation and Swiss Multiple Sclerosis Society. M. Rasenack reports no disclosures. P.H. Lalive is on the scientific advisory board for Biogen-Idec and Novartis and received travel funding and/or speaker honoraria from Biogen-Idec, Teva, and Merck Serono. A.B. Lang is employed by GeNeuro. F. Curtin is employed by GeNeuro. R.L.P. Lindberg received research support from Swiss Multiple Sclerosis Society, Swiss National Science Foundation, and Roche Postdoctoral Fellowship Program. L. Kappos is on the executive board of ECTRIMS; received research support from Mitsubishi Pharma and GeNeuro; is on the executive board of ECTRIMS; received research support from Novartis Pharma, Merck Serono, Biogen-Idec, Swiss National Foundation, and Swiss MS Society; and his spouse is employed by Novartis Pharma. Go to Neurology.org/nn for full disclosure forms. Momotaro is a member of steering committees by Mitsubishi Pharma and GeNeuro; is on the executive board of ECTRIMS; received research support from Novartis Pharma, Merck Serono, Biogen-Idec, Swiss National Foundation, and Swiss MS Society; and his spouse is employed by Novartis Pharma.

REFERENCES


Received March 27, 2015. Accepted in final form July 7, 2015.
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS
Maria Zimmermann, Nicholas S.R. Sanderson, Maria Rasenack, et al.
Neurol Neuroimmunol Neuroinflamm 2015;2;
DOI 10.1212/NXI.0000000000000144

This information is current as of August 20, 2015